Antisense insulin-like growth factor binding protein (igfbp)-2 oligodeoxynucleotides for prostate and other endocrine tumor therapy
CA 2421087 C · Owner: Satoshi, Kiyama · Inventors: Nelson, Colleen; Satoshi, Kiyama; Gleave, Martin
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compositions and a method are provided for the treatment of prostate and other endocrine tumors in mammals, including humans by administration of an , antisense oligodeoxynucleotide (ODN) which is complementary to a portion of the gene encoding IGFBP-2. Using the human prostate cancer LNCaP tumor model in vitro andin vivo, the administration of such an ODN was shown to reduce proliferation of tumor cells, and also to delay the progression to androgen independence. Thus, treatment of prostate and other hormone-regulated cancer in mammals, including humans, and delay of the progression of prostate tumors to androgen independence is accomplished by administering to the mammal a …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 13, 2001 and granted March 27, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 13, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 13, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.